Aptinyx (NASDAQ:APTX) Issues Earnings Results, Beats Expectations By $0.02 EPS

Aptinyx (NASDAQ:APTX – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02, Fidelity Earnings reports. During the same period in the previous year, the business posted ($0.22) earnings per share.

APTX opened at $0.70 on Friday. The stock has a 50-day moving average price of $1.78 and a 200-day moving average price of $2.43. The company has a debt-to-equity ratio of 0.15, a current ratio of 20.18 and a quick ratio of 20.18. The firm has a market cap of $47.40 million, a PE ratio of -0.59 and a beta of 1.46. Aptinyx has a 1 year low of $0.57 and a 1 year high of $4.73.

Several institutional investors and hedge funds have recently bought and sold shares of APTX. Millennium Management LLC raised its position in shares of Aptinyx by 19.7% in the 4th quarter. Millennium Management LLC now owns 1,246,945 shares of the company’s stock worth $3,329,000 after purchasing an additional 205,553 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Aptinyx by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 1,964,058 shares of the company’s stock worth $4,459,000 after purchasing an additional 152,943 shares during the last quarter. Northern Trust Corp raised its position in shares of Aptinyx by 203.7% in the 1st quarter. Northern Trust Corp now owns 219,698 shares of the company’s stock worth $498,000 after purchasing an additional 147,357 shares during the last quarter. Susquehanna International Group LLP raised its position in shares of Aptinyx by 56.8% in the 4th quarter. Susquehanna International Group LLP now owns 243,275 shares of the company’s stock worth $650,000 after purchasing an additional 88,141 shares during the last quarter. Finally, Cetera Advisor Networks LLC purchased a new position in shares of Aptinyx in the 1st quarter worth about $92,000. 55.97% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently commented on APTX. Zacks Investment Research lowered Aptinyx from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. HC Wainwright lowered their price objective on Aptinyx from $8.00 to $2.00 and set a “buy” rating for the company in a research report on Thursday, April 14th. William Blair lowered Aptinyx from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 7th. SVB Leerink lowered their price objective on Aptinyx from $10.00 to $4.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. Finally, Cantor Fitzgerald lowered their price objective on Aptinyx from $11.00 to $5.00 and set an “overweight” rating for the company in a research report on Friday, April 8th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $3.88.

About Aptinyx (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

Recommended Stories